• Orkacept (ORK-001): An investigational antibody therapy designed to treat autoimmune diseases by modulating a specific inflammatory pathway.
• ORK-101: A small molecule inhibitor currently in clinical trials for oncology, targeting a key protein involved in various solid tumors.
• Gene Therapy Platform: A proprietary technology platform focused on developing novel gene therapies for inherited rare genetic disorders.

Oruka Therapeutics (symbol: ORKA) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for dermatological diseases, particularly using its nitric oxide-based technology.

As a clinical-stage company, Oruka Therapeutics is primarily engaged in research and development, and the process of seeking regulatory approval for its drug candidates. Its lead product candidate, SB206 (for molluscum contagiosum), is currently undergoing regulatory review processes and is not yet approved or commercially available on the market.

Therefore, Oruka Therapeutics does not currently have "major customers" in the traditional sense of companies or individuals purchasing commercially available products from them. The company is focused on bringing its therapies to market, at which point its customers would typically include pharmaceutical wholesalers, distributors, pharmacies, healthcare providers, and potentially managed care organizations, with patients being the ultimate beneficiaries of the treatment.

Oruka Therapeutics (ORKA) is developing novel biologics primarily for the treatment of chronic skin diseases, with a significant focus on plaque psoriasis. Their main product candidates include ORKA-001 (an IL-23p19 inhibitor), ORKA-002 (an IL-17A/F inhibitor), and ORKA-021 (a sequential combination regimen of ORKA-002 and ORKA-001).

The addressable market for psoriasis, which Oruka Therapeutics' main products target, is estimated to be approximately $25 billion. This market is also projected to grow to a $40 billion global market for psoriasis biologics by 2035. Oruka's programs collectively target a total market opportunity exceeding $50 billion, which includes psoriasis and other inflammatory and immunology (I&I) indications, and is considered a global market.

Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company focused on developing novel biologics for chronic skin diseases. As the company is currently pre-revenue, its future revenue growth over the next 2-3 years will be primarily driven by the advancement and potential commercialization of its pipeline assets. Analysts currently forecast Oruka Therapeutics to remain unprofitable and without revenue in the near term. However, the key expected drivers for future revenue growth beyond this immediate period are tied to the successful development and potential market entry of its lead product candidates:

• Successful Clinical Development and Potential Commercialization of ORKA-001: ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, is a primary focus for Oruka Therapeutics. The company has completed Phase 1 dosing for ORKA-001 and expects to share data from its Phase 2a EVERLAST-A trial in the second half of 2026. Positive clinical trial results and subsequent regulatory approval would be the most significant driver of future revenue, particularly given its potential for once-yearly or infrequent dosing in plaque psoriasis, which could differentiate it in the market.
• Advancement of ORKA-002 into Later-Stage Clinical Trials: ORKA-002, a novel half-life extended IL-17A/F monoclonal antibody, is also progressing through the pipeline. Its Phase 1 trial is ongoing, with data expected around year-end 2025. The advancement of ORKA-002 into later-stage clinical trials, and ultimately towards regulatory submission, represents another significant potential revenue stream, particularly as it aims for 2-3 times yearly dosing and dual cytokine inhibition for chronic skin diseases.
• Differentiation through Infrequent Dosing and High Disease Clearance Rates: Oruka's strategy to develop novel biologics that offer high rates of complete disease clearance with infrequent dosing (as infrequently as once or twice per year for ORKA-001) is a critical factor in its long-term revenue potential. If successful, this differentiation could lead to strong market adoption and competitive advantage upon commercialization.
• Expansion into Additional Dermatologic and Inflammatory Diseases: While plaque psoriasis is a primary initial target, Oruka Therapeutics is developing its proprietary portfolio of antibodies to target the core mechanisms underlying other dermatologic and inflammatory diseases. Future revenue growth could be driven by the expansion of its product candidates' indications into these additional large markets, leveraging the established efficacy and safety profiles in related conditions.

Share Issuance

• Oruka Therapeutics issued 39,425,806 shares of common stock for approximately $756.19 million after closing a shelf registration on November 8, 2025.
• On September 17, 2025, the company announced a private investment in public equity (PIPE) financing that is expected to generate gross proceeds of approximately $180 million through the sale of common stock and pre-funded warrants.
• Following the merger with ARCA biopharma, a private placement, and a reverse stock split, Oruka Therapeutics had approximately 46.3 million shares of common stock and equivalents in circulation as of September 6, 2024.

Inbound Investments

• On September 17, 2025, Oruka Therapeutics announced a $180 million private placement, with Viking Global Investors as the lead investor, intended to fund research and development, general corporate expenses, and working capital.
• In conjunction with its merger with ARCA biopharma, Oruka completed a $275 million private placement on September 6, 2024, involving investors such as Fairmount, Venrock Healthcare Capital Partners, and Blackstone Multi-Asset Investing.
• The company raised over $475 million in 2024 from its go-public transaction and private placements, providing cash runway through multiple clinical milestones.

Capital Expenditures

• Capital expenditures for the last 12 months, as of October 31, 2025, were reported at approximately -$253,182.
• The primary focus of capital allocation, particularly from recent financings, is on research and development for its lead drug candidates, ORKA-001 and ORKA-002, aimed at treating chronic skin diseases.